Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.
The Opportunity:
The Executive Director, Investor Relations will serve as a strategic leader responsible for defining, elevating, and executing Revolution Medicines’ global investor relations strategy during a pivotal transition to a commercial-stage organization. This individual will act as a key advisor to senior leadership, helping shape how the company’s evolving clinical, regulatory, and commercial story is communicated to the investment community
This role will be instrumental in positioning the company for long-term value creation as it approaches product launches, advances and expands its pipeline, and navigates increasingly complex capital markets dynamics. The Executive Director will lead all aspects of the investor relations function, oversee engagement with the investment community, and ensure the company’s narrative effectively reflects its transition from a development-stage to a commercial-stage enterprise.
This position will report to the Senior Vice President of Corporate Affairs and work closely with the CEO and broader executive team. The role will also be responsible for building and leading a high-performing investor relations function.
Key Responsibilities:
Accountable for enterprise-level IR strategic planning, long-term external positioning, and integration of IR strategy with broader corporate objectives.
Serve as a spokesperson to the investment community, building trusted relationships with institutional investors, analysts, and key stakeholders.
Advise senior leadership on investor sentiment, market dynamics, and external perception, particularly as the company approaches key inflection points.
Collaborate with Corporate Communications to shape and continuously evaluate the company’s narrative to reflect its evolution, including clear articulation of clinical data, R&D strategy, and commercialization.
Lead the quarterly earnings process and broader financial communications strategy, ensuring messaging reflects both near-term execution and long-term growth potential.
Drive investor targeting and engagement strategies, including conferences, non-deal roadshows, and investor events, with an emphasis on expanding the company’s shareholder base to include high-quality, long-term oriented investors.
Partner cross-functionally with R&D, clinical, regulatory, commercialization, finance, and corporate affairs teams to ensure consistency, accuracy, and strategic alignment of external communications.
Anticipate and proactively address investor questions.
Align investor communications with broader corporate messaging, including ESG strategy and external positioning.
Ensure best practices in disclosure, compliance, and governance as the company’s external visibility and complexity increase.
Required Skills, Experience, and Education:
The successful candidate will be an experienced executive with a strong track record of leadership in investor relations within the biopharmaceutical industry, ideally with experience supporting companies through late-stage development and into commercialization.
Bachelor’s degree required; advanced degree (MBA, PhD, or equivalent) strongly preferred.
10+ years of relevant experience, including progressive leadership experience in investor relations, corporate affairs, or finance within biotech/pharmaceuticals.
Demonstrated experience supporting a company through late-stage clinical development, regulatory milestones, and/or commercial launch.
Deep understanding of capital markets, investor expectations, and valuation drivers for both development-stage and commercial-stage biopharmaceutical companies.
Strong knowledge of clinical development, regulatory pathways, market access, and commercialization strategies.
Proven ability to influence and advise senior executives.
Exceptional communication skills, with the ability to translate complex scientific, clinical, and commercial information into clear, compelling narratives.
Proven experience managing high-profile investor interactions during periods of significant corporate transition.
Strong analytical, strategic, and problem-solving capabilities.
High level of executive presence, credibility, and judgment.
Ability to operate effectively and independently in a fast-paced, dynamic, and evolving organization.
#LI-Remote #LI-JW1
The base pay salary range for this full-time position for candidates working onsite at our headquarters in Redwood City, CA is listed below. The range displayed on each job posting is intended to be the base pay salary range for an individual working onsite in Redwood City and will be adjusted for the local market a candidate is based in. Our base pay salary ranges are determined by role, level, and location. Individual base pay salary is determined by multiple factors, including job-related skills, experience, market dynamics, and relevant education or training.
Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Revolution Medicines is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital status, medical condition, and veteran status.
Revolution Medicines takes protection and security of personal data very seriously and respects your right to privacy while using our website and when contacting us by email or phone. We will only collect, process and use any personal data that you provide to us in accordance with our CCPA Notice and Privacy Policy. For additional information, please contact [email protected].
We are aware of recent recruitment scams in which individuals or organizations falsely represent themselves as being affiliated with Revolution Medicines. These scams may appear as false job advertisements or unsolicited contacts through communication or chat platforms, email, phone, or text message.
Please note that Revolution Medicines does not extend unsolicited employment offers and will never ask candidates to provide financial information, purchase equipment, or pay fees as part of the hiring process. All legitimate communication from Revolution Medicines will come from an official @revmed.com email address.
If you believe you’ve been contacted by someone impersonating a Revolution Medicines recruiter, please report it to [email protected] so we can share these impersonations with our IT team for tracking and awareness.
Skills Required
- Bachelor's degree
- Advanced degree (MBA, PhD, or equivalent) strongly preferred
- 10+ years of relevant experience in investor relations, corporate affairs, or finance
- Demonstrated experience in late-stage clinical development and commercialization
- Deep understanding of capital markets and pharmaceutical industry
- Exceptional communication skills
- Proven experience managing high-profile investor interactions
- Strong analytical, strategic, and problem-solving capabilities
What We Do
We are Revolutionaries – passionate in our singular pursuit of discovering, developing and delivering innovative, targeted medicines for patients living with cancer. To deliver on our vision, we work relentlessly in pursuit of cutting-edge therapeutic approaches to some of the toughest cancers. Our current focus is on RAS-addicted cancers, which account for 30 percent of all new human cancer diagnoses
